本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 宁波三星医疗电气股份有限公司（以下简称"公司"）下属全资子公司 Nansen Instrumentos de Precisão Ltda（以下简称"巴西南森"）签订巴西 CPFL 智能电表项目 合同，合同金额总计 10,590.99 万雷亚尔，约合 1.35 亿人民币。具体情况如下： 一、交易概述 巴西南森签订巴西 CPFL 智能电表项目合同，公司作为供应商，提供单相智能 电表、三相智能电表等产品，合同金额总计 10,590.99 万雷亚尔，约合 1.35 亿人民币。 证券代码：601567 证券简称：三星医疗 公告编号：临 2025-096 宁波三星医疗电气股份有限公司 关于子公司签订海外经营合同的公告 2、合同金额：总计 10,590.99 万雷亚尔，约合 1.35 亿人民币 四、合同履行对公司的影响 本次合同金额约合 1.35 亿人民币，占公司 2024 年度经审计营业收入的 0.92%。 合同的履行将对公司的经营工作和经营业绩产生积极影响，但对公司业务 ...

Core Viewpoint - Samsung Medical (601567.SH) has signed a contract for the Brazil CPFL smart meter project, marking a significant step in expanding its overseas market presence and localizing its operations [1] Group 1: Contract Details - The contract was signed by Samsung Medical's wholly-owned subsidiary, Brazil Nansen, and involves the supply of single-phase and three-phase smart meters [1] - The total contract amount is 10,590.99 million Brazilian Reais, approximately 135 million RMB [1] - This contract represents about 0.92% of the company's audited revenue for the fiscal year 2024 [1] Group 2: Impact on Business - The execution of this contract is expected to have a positive impact on the company's operational performance and business results [1] - The signing of this contract reflects the company's efforts to actively explore overseas markets and deepen its local layout [1] - The contract will help the company enhance its overseas business layout and improve its competitive advantage in international markets [1]

Core Viewpoint - Samsung Medical (601567.SH) has signed a contract for the Brazil CPFL smart meter project, marking a significant step in expanding its overseas market presence and localizing operations [1] Group 1: Contract Details - The contract was signed by the company's wholly-owned subsidiary, Brazil Nansen, to supply single-phase and three-phase smart meters [1] - The total contract amount is 10,590.99 million Brazilian Reais, approximately 135 million RMB [1] - This contract represents about 0.92% of the company's audited revenue for the fiscal year 2024 [1] Group 2: Impact on Business - The execution of this contract is expected to have a positive impact on the company's operational performance [1] - The contract will not affect the independence of the company's business operations [1] - This signing is a result of the company's efforts to actively explore overseas markets and deepen local layouts, enhancing its competitive advantage in international markets [1]

三星医疗公告，下属全资子公司巴西南森签订巴西CPFL智能电表项目合同，合同金额总计1.06亿雷亚 尔，约合1.35亿人民币，占公司2024年度经审计营业收入的0.92%。公司将提供单相和三相智能电表等 产品。该合同的签订是公司积极拓展海外市场、深化本地化布局的重要成果，有助于提升公司的海外市 场竞争力。合同的履行将对公司经营业绩产生积极影响。 ...

人民财讯12月24日电，三星医疗（601567）12月24日公告，下属全资子公司巴西南森签订巴西CPFL智 能电表项目合同，合同金额总计1.06亿雷亚尔，约合1.35亿元人民币，占公司2024年度营业收入的 0.92%。 ...

Group 1 - The core point of the article is that Samsung Medical (601567.SH) has signed a contract for a smart meter project in Brazil with CPFL, amounting to 105.9099 million Brazilian Reais, which is approximately 135 million Chinese Yuan [1] Group 2 - The contract is executed through Nansen Instrumentos de Precisão Ltda, a wholly-owned subsidiary of Samsung Medical [1] - The project signifies Samsung Medical's expansion into the Brazilian market, particularly in the smart meter sector [1] - The financial implications of the contract could enhance the company's revenue and market presence in Latin America [1]

证券日报网讯12月23日，三星医疗（601567）在互动平台回答投资者提问时表示，公司主营业务为智能 配用电及医疗服务两大板块，未涉及可控核聚变领域。 ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：贵司是否涉及可控核聚变领域？ 三星医疗（601567.SH）12月23日在投资者互动平台表示，公司主营业务为智能配用电及医疗服务两大 板块，未涉及可控核聚变领域。 ...

针对上述提问，三星医疗回应称："尊敬的投资者，您好！公司主营业务为智能配用电及医疗服务两大 板块，未涉及可控核聚变领域。感谢您的关注！" 有投资者在互动平台向三星医疗提问："贵司是否涉及可控核聚变领域？" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 ...

格隆汇12月23日丨三星医疗(601567.SH)在投资者互动平台表示，公司主营业务为智能配用电及医疗服 务两大板块，未涉及可控核聚变领域。 ...